248 related articles for article (PubMed ID: 29228144)
1. Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
Moore DJ; Jain S; Dubé MP; Daar ES; Sun X; Young J; Corado K; Ellorin E; Milam J; Collins D; Blumenthal J; Best BM; Anderson P; Haubrich R; Morris SR
Clin Infect Dis; 2018 May; 66(10):1566-1572. PubMed ID: 29228144
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study.
Morris SR; Jain S; Blumenthal J; Bolan R; Dubé MP; Henderson P; Corado K; Sun S; He F; Chow K; Burke L; Anderson PL; Moore DJ
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):453-459. PubMed ID: 36084200
[TBL] [Abstract][Full Text] [Related]
3. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
[TBL] [Abstract][Full Text] [Related]
4. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
Celum C; Hosek S; Tsholwana M; Kassim S; Mukaka S; Dye BJ; Pathak S; Mgodi N; Bekker LG; Donnell DJ; Wilson E; Yuha K; Anderson PL; Agyei Y; Noble H; Rose SM; Baeten JM; Fogel JM; Adeyeye A; Wiesner L; Rooney J; Delany-Moretlwe S
PLoS Med; 2021 Jun; 18(6):e1003670. PubMed ID: 34143779
[TBL] [Abstract][Full Text] [Related]
5. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
Yager J; Castillo-Mancilla J; Ibrahim ME; Brooks KM; McHugh C; Morrow M; McCallister S; Bushman LR; MaWhinney S; Kiser JJ; Anderson PL
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):323-330. PubMed ID: 32539288
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
Pyra M; Anderson PL; Hendrix CW; Heffron R; Mugwanya K; Haberer JE; Thomas KK; Celum C; Donnell D; Marzinke MA; Bukusi EA; Mugo NR; Asiimwe S; Katabira E; Baeten JM;
AIDS; 2018 Aug; 32(13):1891-1898. PubMed ID: 29894385
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
Spinelli MA; Glidden DV; Anderson PL; Gandhi M; Cohen S; Vittinghoff E; Coleman ME; Scott H; Bacon O; Elion R; Kolber MA; Buchbinder SP; Liu AY
J Acquir Immune Defic Syndr; 2019 Jun; 81(2):158-162. PubMed ID: 31095005
[TBL] [Abstract][Full Text] [Related]
8. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
[TBL] [Abstract][Full Text] [Related]
9. Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial.
Aizire J; Brooks KM; Mirochnick M; Flynn PM; Butler K; Kiser JJ; Siberry GK; Fenton T; Cababasay M; Fowler MG;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):173-180. PubMed ID: 31929405
[TBL] [Abstract][Full Text] [Related]
10. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ;
Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303
[TBL] [Abstract][Full Text] [Related]
11. Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.
Liu AY; Vittinghoff E; von Felten P; Rivet Amico K; Anderson PL; Lester R; Andrew E; Estes I; Serrano P; Brothers J; Buchbinder S; Hosek S; Fuchs JD
Clin Infect Dis; 2019 May; 68(12):2010-2017. PubMed ID: 30239620
[TBL] [Abstract][Full Text] [Related]
12. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of Plasma Efavirenz and Tenofovir, Dried Blood Spot Tenofovir-Diphosphate, and Self-Reported Adherence to Predict Virologic Suppression Among South African Women.
Phillips TK; Sinxadi P; Abrams EJ; Zerbe A; Orrell C; Hu NC; Brittain K; Gomba Y; Norman J; Wiesner L; Myer L; Maartens G
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):311-318. PubMed ID: 30893125
[TBL] [Abstract][Full Text] [Related]
14. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
[TBL] [Abstract][Full Text] [Related]
15. Concordance between daily diary reported pre-exposure prophylaxis intake and intraerythrocytic tenofovir diphosphate in the Amsterdam Pre-exposure Prophylaxis demonstration project.
Wijstma ES; Jongen VW; Boyd A; van den Elshout MAM; de Vries HJC; Davidovich U; Anderson PL; Prins M; Hoornenborg E; Schim van der Loeff MF
AIDS; 2024 Jul; 38(8):1248-1256. PubMed ID: 38518076
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
Castillo-Mancilla JR; Morrow M; Coyle RP; Coleman SS; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; Mawhinney S; Anderson PL
Clin Infect Dis; 2019 Apr; 68(8):1335-1342. PubMed ID: 30137238
[TBL] [Abstract][Full Text] [Related]
17. Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
Grant RM; Pellegrini M; Defechereux PA; Anderson PL; Yu M; Glidden DV; O'Neal J; Yager J; Bhasin S; Sevelius J; Deutsch MB
Clin Infect Dis; 2021 Oct; 73(7):e2117-e2123. PubMed ID: 32766890
[TBL] [Abstract][Full Text] [Related]
18. Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
van den Elshout MA; Hoornenborg E; Coyer L; Anderson PL; Davidovich U; de Vries HJ; Prins M; Schim van der Loeff MF;
Sex Transm Infect; 2023 Aug; 99(5):303-310. PubMed ID: 37258273
[TBL] [Abstract][Full Text] [Related]
19. Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
Marins LMS; Torres TS; Leite IDC; Moreira RI; Luz PM; Hoagland B; Kallas EG; Madruga JV; Liu AY; Anderson PL; Grinsztejn B; Veloso VG
PLoS One; 2019; 14(8):e0221281. PubMed ID: 31430318
[TBL] [Abstract][Full Text] [Related]
20. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
Goldwirt L; Bauer R; Liegeon G; Charreau I; Delaugerre C; Cotte L; Pialou G; Cua E; Laghzal A; Buschman L; Anderson PL; Mourah S; Meyer L; Molina JM;
J Antimicrob Chemother; 2021 Sep; 76(10):2675-2680. PubMed ID: 34278433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
